3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Breast
29
Gastrointestinal
17
Gynecologic
7
Tumor-Agnostic
5
Thoracic
5
CNS
4
Sarcoma
3
Head & Neck
3
Genitourinary
2
Dermatologic
1
Conditions
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Astrocytoma
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
Magnetic Resonance Spectroscopy
106
Specimen Handling
87
pembrolizumab
81
enzalutamide
64
Nivolumab
62
Gemcitabine
59
Docetaxel
51
Abiraterone Acetate
44
apalutamide
43
Radiosurgery
43
Androgen Antagonists
43
Prednisone
42
darolutamide
40
Cisplatin
38
Biopsy
36
Radiotherapy
34
cabozantinib
32
Carboplatin
30
abiraterone
29
Pluvicto
29
Ipilimumab
29
durvalumab
25
Leuprolide
24
enfortumab vedotin
23
X-Rays
23
Radiation
23
olaparib
20
atezolizumab
20
Standard of Care
20
avelumab
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
trastuzumab deruxtecan
×
Genitourinary
×
90 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled